AbVitro, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
AbVitro, Inc. - overview
Location
Boston, MA, US
Primary Industry
Biotechnology
About
Founded in 2010 and based in Massachusetts, US, AbVitro, Inc. develops an antibody discovery platform for the treatment of autoimmune diseases and cancer. AbVitro’s technology allows for the identification of fully human, natively paired T-cell receptors (TCRs) and chimeric antigen receptor (CAR) T-binders directly from cancer patients. In June 2013, AbVitro, Inc.
raised USD 1. 873 million in Series A financing from Santé Ventures, and in 2016, the company was acquired by Juno Therapeutics for USD 135 million in cash and stock.
Current Investors
Sante Ventures
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment
Company Stage
Acquired
Total Amount Raised
Subscriber access only
AbVitro, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.